Free Trial

Esperion Therapeutics (ESPR) Stock Forecast & Price Target

$2.45
+0.09 (+3.81%)
(As of 07/5/2024 ET)

Esperion Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$8.83
260.54% Upside
High Forecast$16.00
Average Forecast$8.83
Low Forecast$2.50
TypeCurrent Forecast
7/7/23 to 7/6/24
1 Month Ago
6/7/23 to 6/6/24
3 Months Ago
4/8/23 to 4/7/24
1 Year Ago
7/7/22 to 7/7/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$8.83$9.33$9.33$11.44
Forecasted Upside260.54% Upside317.04% Upside316.29% Upside160.52% Upside

ESPR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ESPR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Esperion Therapeutics Stock vs. The Competition

TypeEsperion TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.71
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside260.54% Upside996.42% Upside12.25% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/28/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00+280.95%
6/28/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00+592.64%
6/20/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$2.90 ➝ $2.50-8.09%
11/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral
8/1/2023Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnder Perform ➝ Market Perform
3/7/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral$6.50 ➝ $7.00+37.93%
New Government Policy to Wipe Out Seniors Wealth (Ad)

Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.

Click Here To Get Your FREE Guide Now!
3/6/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform$15.00+136.59%
2/24/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$12.00+105.83%
2/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$9.00+52.03%
8/9/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$13.00+103.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:29 AM ET.

ESPR Forecast - Frequently Asked Questions

What is Esperion Therapeutics' forecast for 2024?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Esperion Therapeutics is $8.83, with a high forecast of $16.00 and a low forecast of $2.50.

Should I buy or sell Esperion Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There is currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.

Does Esperion Therapeutics's stock price have much upside?

According to analysts, Esperion Therapeutics's stock has a predicted upside of 271.67% based on their 12-month stock forecasts.

Has Esperion Therapeutics been downgraded by Wall Street analysts recently?

Over the previous 90 days, Esperion Therapeutics's stock had 1 downgrade by analysts.

What analysts cover Esperion Therapeutics?

Esperion Therapeutics has been rated by research analysts at Bank of America, HC Wainwright, and Needham & Company LLC in the past 90 days.

Do Wall Street analysts like Esperion Therapeutics more than its competitors?

Analysts like Esperion Therapeutics less than other "medical" companies. The consensus rating for Esperion Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ESPR compares to other companies.


This page (NASDAQ:ESPR) was last updated on 7/6/2024 by MarketBeat.com Staff

From Our Partners